Dolphin Entertainment 주식 (NASDAQ: DLPN)

에 대한 최신 뉴스 Dolphin Entertainment (NASDAQ:DLPN) 주식

Dolphin Entertainment

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

Dolphin Entertainment, Inc. - Common Stock

Dolphin Entertainment Inc

During the last three months, 11 analysts shared their evaluations of VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for VF, revealing an average target of $18.45, a high estimate of $28.00, and a low estimate of $12.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 29.85%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224059_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive VF. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to VF. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of VF compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of VF's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into VF's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VFC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on VF analyst ratings.</a>
<h2>About VF</h2>
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 11 brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
<h3>VF: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining VF's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.93% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.92%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): VF's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.87% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): VF's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.47% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: VF's debt-to-equity ratio is below the industry average at 3.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About VF Stock

Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 1100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $9.73 million which missed the analyst consensus estimate of $10.90 million by 10.70 percent. This is a 20.77 percent decrease over sales of $12.29 million the same period last year.

Earnings

Earnings Misses

News

CREX

Creative Realities Q1 Adj. EPS $(0.12), Inline, Sales $9.73M Miss $10.90M Estimate

Across the recent three months, 6 analysts have shared their insights on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.83, a high estimate of $10.00, and a low estimate of $7.00. Surpassing the previous average price target of $8.17, the current average has increased by 8.08%.
<img src="https://www.benzinga.com/files/images/story/2025/1747224021_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Absci. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Absci. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Absci compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Absci's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Absci's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Absci analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Absci</h2>
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
<h3>Breaking Down Absci's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Absci's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 96.75%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Absci's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -4358.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Absci's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Absci's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -12.91%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

Assessing Absci: Insights From 6 Financial Analysts

On May 11, 2025, Incyte Corporation (the "Company") and Novartis Pharma AG ("Novartis") entered into a settlement agreement (the "Settlement Agreement") with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalties relating to the dispute with Novartis included in accrued and other current liabilities on the Company's condensed consolidated balance sheet. Under the Settlement Agreement, the Company has agreed to pay to Novartis $280.0 million as the settlement of disputed royalties on net sales of JAKAFI in the United States through December 31, 2024, and the parties agreed to reduce by 50% the royalty rate payable by the Company on future net sales of JAKAFI in the United States beginning January 1, 2025 for a period defined in the Settlement Agreement. The reduced royalty payable for the quarter ended March 31, 2025, is approximately $14.9 million. The difference of $242.2 million between the total accrued royalties and the total amount to be paid by the Company to Novartis as disclosed above will be recorded in the Company's condensed consolidated statement of operations for the quarter ending June 30, 2025.

Contracts

Legal

INCY

Incyte And Novartis Settle Royalty Dispute With $280M Payment And 50% Reduction In Future JAKAFI U.S. Royalties, Resolving Litigation Over 2009 Collaboration Agreement And Releasing $242.2M In Accrued Liabilities

Leerink Partners analyst Daina Graybosch downgrades ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Outperform to Market Perform and lowers the price target from $47 to $9.

Downgrades

Price Target

ITOS

Leerink Partners Downgrades ITeos Therapeutics to Market Perform, Lowers Price Target to $9

Channel Therapeutics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NYSE">CHRO</a>) announced on Wednesday that it has achieved its predefined endpoints in two preclinical animal models for eye drop formulations (CT2000) for acute ocular and chronic ocular surface pain commonly associated <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">with dry eye disease</a>.&nbsp;
"We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42552299/channel-therapeutics-announces-positive-efficacy-data-for-a-depot-formulation-of-a-nav1-7-inhibito" rel="noreferrer noopener">announced in December 2024</a>, demonstrating a viable path forward in treating both post-surgical pain and chronic eye pain," stated Dr. Eric Lang, Chief Medical Officer of Channel.
"Additionally, these results support our belief that the inhibition of NaV1.7 has broad applications in treating different pain indications and further supports the genetic validation that NaV1.7 is a potent target for pain," concluded Dr. Lang.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44858815/exclusive-ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics-creating-pain-medicines-focused-entity" rel="noreferrer noopener">EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity</a>
In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult.
<ul class="wp-block-list">
<li>Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over 24 hours.</li>
<li>Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models).</li>
<li>The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administering capsaicin and continued to show efficacy over 60 minutes following administration. </li>
</ul>
In the second trial, benzalkonium chloride (BAC) was instilled in the eyes of mice over a multiday period to create a model of dry eye disease (the study was repeated twice).
<ul class="wp-block-list">
<li>BAC is a detergent that irritates the eyes and simulates dry eye disease.</li>
<li>Following the induction of dry eye using BAC, the mice were dosed with CT2000 four times daily for seven days.</li>
<li>CT2000 reduced the frequency of paw wipes within a single day of administration and showed cumulative efficacy over time (the analgesic effect appeared to improve when dosed over several days). </li>
</ul>
"We are very encouraged with these results, and the opportunity to target a large market that currently does not have many therapeutic options could provide Channel with considerable market opportunities," stated Frank Knuettel II, CEO of Channel. "Moreover, these results pave the way for Channel to launch Phase 1/2 human proof of concept trials," Mr. Knuettel concluded.
According to Astute Analytica, the global annual chronic eye pain market was valued at $7.2 billion in 2023 and is projected to reach $12.4 billion by 2032, at a compound annual growth rate of 6.6% from 2024 to 2032.
According to Marketresearch.biz, the global annual acute eye pain market was valued at $404 million. The company intends to target this existing market with CT2000 and the postoperative pain market.
Price Action: CHRO stock closed at $1.07 on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45394076/cpi-undershoots-but-core-inflation-stays-stubborn-jp-morgan" target="_blank" rel="noreferrer noopener">CPI Undershoots But Core Inflation Stays Stubborn: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

CHRO

EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models

WIIM

QNRX

Quoin Pharmaceuticals shares are trading higher after the company announced initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.

ALCO

UPDATE: Alico Q2 Adj. EPS $(10.98), Sales $17.98M Miss $22.20M Estimate

Back in 1995, Bill Gates appeared on The Late Show with David Letterman, where he tried to explain what the internet was to the host, and seemingly predicted the emergence of AI.
What Happened: During their <a href="https://www.youtube.com/watch?v=fs-YpQj88ew">conversation</a>, Letterman asked Gates about the value of the then-new internet. Gates described it as a space "where people are publishing information," noting, "everybody can have their own homepage… it&#8217;s wild what&#8217;s going on."
When Letterman pushed him to share what he thought the future of the computer might be, Gates said: "Eventually we may figure out how to make the computer think… that turns out to be a very tough problem… nobody knows when that&#8217;ll happen. Some people think it&#8217;ll never happen." When Letterman quipped, "We don&#8217;t want them to think, do we?" Gates responded, "Not really… it&#8217;s a scary thought."
See Also: <a href="https://www.benzinga.com/25/05/45379222/former-google-ceo-eric-schmidt-in-2016-outlined-a-playbook-predicting-chatgpts-rise-and-a-new-age-of-100-billion-ai-giants">Former Google CEO Eric Schmidt In 2016 Outlined A Playbook Predicting ChatGPT&#8217;s Rise — And A New Age Of $100 Billion AI Giants</a>
Why It Matters: Although this conversation took place in 1995, before AI as we know it was developed, Gates' skepticism has persisted. Earlier this year, he listed <a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues">improper development of AI</a> as one of the critical challenges future generations will face, alongside nuclear war, bioterrorism and climate change.  
Last year, he highlighted a paradox at the heart of AI's unprecedented rise: while it promises to reduce the need for human effort and increase leisure time, it also raises questions about <a href="https://www.benzinga.com/news/24/12/42438799/bill-gates-predicts-ai-in-the-workforce-will-lead-to-so-much-leisure-time-but-itll-create-a-what-do-we-do-with-all-that-time-problem">how humans use that time</a>. He also emphasized the importance of regulatory oversight to prevent harm, such as biased results or dangerous misinformation.
In a recent television appearance, Gates pointed out that <a href="https://www.benzinga.com/news/25/05/45342962/bill-gates-slams-trumps-tariffs-we-told-china-to-make-their-own-chips-and-theyre-making-great-progress-warns-its-a-bad-time-to-inte">U.S. tariffs and tech restrictions have accelerated China&#8217;s move towards self-reliance</a>, especially in chip development. He highlighted that with open-source tools accessible globally, no single country is likely to dominate AI.
Read Next: <a href="https://www.benzinga.com/25/05/45377433/bill-gates-announces-plan-to-close-the-gates-foundation-says-hell-give-away-virtually-all-of-his-wealth-over-the-next-20-years">Bill Gates Announces Plan To Close The Gates Foundation, Says He&#8217;ll Give Away &#8216;Virtually All&#8217; Of His Wealth Over The Next 20 Years</a>
Image via Shutterstock

Entertainment

Markets

Tech

Bill Gates Once Warned That Computers Might Eventually Think On Their Own—But Admitted It Was A 'Scary Thought' That 'No One Knows When That Will Happen'

LUCY

Innovative Eyewear shares are trading higher after the company reported better-than-expected Q1 sales results.

ZVRA

Zevra Therapeutics shares are trading higher after the comapny reported better-than-expected Q1 financial results.

JP Morgan analyst Michael Cho assumes Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) with a Neutral rating and announces Price Target of $18.

Initiation

FRGE

JP Morgan Assumes Forge Global Holdings at Neutral, Announces Price Target of $18

Avis Budget Announced That Its Wholly-owned Subsidiaries Intend, Subject To Market And Other Customary Conditions, To Offer $500M Aggregate Principal Amount Of Senior Notes Due 2032 In A Private Offering

OpenAI chief Sam Altman describes Airbnb CEO Brian Chesky as someone who loves to express his individuality and influence through his work as a founder, a quality he thinks comes through during Airbnb&#8217;s launches.
What Happened: Altman lit up X after Chesky posted a teaser for Airbnb's sweeping overhaul, writing, "Brian is the most auteur founder of this generation, and it really shines through in how he does launches!" and later adding, "the new app design is so great."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">brian is the most auteur founder of this generation, and it really shines through in how he does launches! <a href="https://t.co/BSgjUsCMzq">https://t.co/BSgjUsCMzq</a>
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1922372362420256960?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Altman's praise landed hours after Chesky unveiled Airbnb's radical shift in the direction of being an &#8220;everything app.&#8221; "Now, you can Airbnb more than an Airbnb," Chesky told a Tuesday crowd, promising to turn every trip or hometown weekend into a curated itinerary.
Chesky introduced the three pillars for the platform: Airbnb Services, a re-engineered Airbnb Experiences, and an all-new app tying them together. The headline addition, Airbnb Services, lets users in 260 cities book in-home chefs, massages, personal trainers and even makeup artists, matching perks long monopolized by hotels.
See also: <a href="https://www.benzinga.com/markets/equities/25/05/45402695/teslas-robotaxi-plans-under-federal-scrutiny-ahead-ff-austin-launch-as-elon-musk-vows-nationwide-rollout-by-year-end">Tesla&#8217;s Robotaxi Plans Under Federal Scrutiny Ahead Ff Austin Launch As Elon Musk Vows Nationwide Rollout By Year-End</a>
The rebooted Experiences hub ditches bus-tour clichés for five lanes—history &amp; culture, food &amp; drink, nature &amp; outdoors, art &amp; design, and fitness &amp; wellness — ranging from restoring Notre Dame with its architects to ramen lessons from Michelin-star chefs.
Airbnb is also rolling out Originals, limited-slot events hosted by names like Megan Thee Stallion and NFL MVP Patrick Mahomes.
A ground-up app redesign was also launched at the event, which features countdown widgets, interactive icons and AI-driven suggestions into a single itinerary view that mashes lodging, services and experiences.
Why It Matters: Wall Street analysts <a href="https://www.benzinga.com/25/05/45175845/wall-street-reacts-as-airbnb-eyes-growth-amid-us-slowdown-details">told Benzinga</a> the summer release is meant to open new revenue lanes as Airbnb's core bookings mature, even as regulatory and hotel competition pressures persist.
Altman, in a blog post earlier this year, publicly stated that Chesky and SV Angel founder Ron Conway did "incredible and gigantic amounts of work" helping him during his <a href="https://www.benzinga.com/news/23/12/36171063/what-really-happened-with-sam-altman-getting-fired-as-openai-ceo-new-details-emerge">brief ouster from OpenAI</a> in November 2023. Altman added that the pair "stopped me from making several mistakes," and suggested OpenAI might not still be standing without their support.
Photo by Boumen Japet via Shutterstock
Read next: <a href="https://www.benzinga.com/news/25/05/45403040/jeff-bezos-became-a-billionaire-after-taking-this-leap-of-faith-would-you-have-the-stomach-for-his-regret-minimization-strategy">Jeff Bezos Became A Billionaire After Taking This Leap Of Faith: Would You Have The Stomach For His &#8216;Regret-Minimization&#8217; Strategy?</a>

Brian Chesky Shares Promo For Airbnb's Biggest Change In Decades, Sam Altman Calls Him 'The Most Auteur Founder Of This Generation'

MediPharm Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MEDIF#OTC">MEDIF</a>) reported quarterly sales of $7.53 million which missed the analyst consensus estimate of $10.54 million by 28.59 percent. This is a 3.85 percent increase over sales of $7.25 million the same period last year.

MEDIF

MediPharm Labs Q1 Sales $7.53M Miss $10.54M Estimate

<ul class="wp-block-list">
<li>Walgreens has plans to expand its use of robot-powered micro-fulfillment centers</li>
<li>The centers currently serve 4,800 stores, and fill more than 16 million prescriptions each month</li>
<li>The push for automation comes as Walgreens prepares to go private in a deal with Sycamore Partners</li>
</ul>
Walgreens will be expanding its use of prescription-filling robots, <a href="https://www.cnbc.com/2025/05/11/walgreens-doubles-down-on-robots-to-fill-prescriptions-amid-turnaround.html">CNBC</a> reports.
The pharmacy chain began using micro-fulfillment centers in 2021 before pausing the program in 2023 to focus on feedback and improvement. Now, it&#8217;s working to add more in order to free up time for pharmacy staff, reduce time spent on routine tasks, and eliminate inventory waste.
The robot-powered centers fill thousands of prescriptions for patients who use medication to manage conditions like diabetes and high blood pressure. With those tasks automated, Walgreens told CNBC its pharmacy staff will have more time to interact directly with patients and perform clinical services like vaccinations and testing.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
The company told CNBC it hopes to have 11 micro-fulfillment centers serving 5,000 locations by the end of the year. In February, there were 4,800 stores that utilized the micro-fulfillment centers. On average, these centers handled 40% of the prescription volume at the individual locations, Walgreens says, which translates to about 16 million prescriptions filled each month across all serviced stores.
Kayla Heffington, Walgreens' pharmacy operating model vice president, told CNBC that the company's investment in automation is already paying off. The micro-fulfillment centers have generated $500 million in savings through their increased efficiency and reduction of excess inventory. Stores that use the centers are also administering 40% more vaccines than those that aren't, increasing profits.
"Right now, [the micro-fulfillment centers] are the backbone to really help us offset some of the workload in our stores, to obviously allow more time for our pharmacists and technicians to spend time with patients," Rick Gates, Walgreens' chief pharmacy officer, told CNBC. "It gives us a lot more flexibility to bring down costs, to increase the care and increase speed to therapy – all those things."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Gates added that he sees the micro-fulfillment centers as a competitive advantage for Walgreens, because many independent pharmacies and larger rivals don't have the centralized support. However, many of Walgreens' major competitors, like Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), and Albertsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), already have, or are testing, their own versions of the micro-fulfilment facilities.&nbsp;
There are, of course, risks that come with using these micro-fulfillment centers, like a reliance on sophisticated robotics that can cause major disruptions if errors occur. But for Walgreens, the rewards heavily outweigh the risks.
Heffington told CNBC that the automated locations have helped reduce prescription fulfillment costs by nearly 13% year over year, and have increased prescription volume by 126%. The centers also allow the company to have real-time data on all prescription fulfillments, enabling its employees to provide better customer service.&nbsp;
The renewed push for automation comes as Walgreens prepares to go private in a <a href="https://investor.walgreensbootsalliance.com/news-releases/news-release-details/walgreens-boots-alliance-enters-definitive-agreement-be-acquired">$10 billion deal with Sycamore Partners</a>. The buyout is expected to be complete by the end of the year.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Image: Shutterstock

Personal Finance

Walgreens To Expand Use Of Prescription-Filling Robots, Cites $500 Million In Savings As Motive

EXCLUSIVE: Channel Therapeutics Tells Benzinga Co. Announces Results For The Treatment Of Eye Pain Using NaV1.7 Inhibitor In Multiple Preclinical In Vivo Models

RCAT

Red Cat Holdings shares are trading higher after the company announced the expansion of its multi-domain Family of Systems with a new line of Unmanned Surface Vessels.

VERV

Verve Therapeutics shares are trading higher after the company reported a year-over-year increase for Q1 EPS results.

ARCO

Arcos Dorados Holdings shares are trading lower after the company reported mixed Q1 financial results.

Press Releases

Dolphin CEO Bill O'Dowd Starts $250,000 10b5-1 Stock Purchase Plan This Week, Building on $100,000 Purchase in 2H 2024; Bullish on Dolphin's Undervalued Shares and Future Growth

Events

Dolphin to Present at the LD Micro Investor Conference in New York City on April 10, 2025 at 2:00pm ET

Dolphin Subsidiary Special Projects Springs into the New Season, Partnering with MAX, Warner Bros. and Louis Vuitton

Dolphin CEO Bill O'Dowd Featured on CEO.com Podcast: from Bedroom Startup to Media Powerhouse

Dolphin Subsidiary the Digital Dept. Hosts Highest-Grossing BRANDEdit Influencer Experience to Date in Los Angeles

Longtime Shore Fire Media Client Cyndi Lauper To Be Inducted Into Rock & Roll Hall of Fame

Dolphin Clients Shine at the 2025 Met Gala

Dolphin to Host First Quarter 2025 Earnings Call on May 13 at 4:30 PM ET

Dolphin Subsidiary The Digital Dept. Sees Surge In Affiliate Marketing Division, Driving Over $6.6 Million In Gross Retail Sales In First Quarter

Dolphin Reports Q1 2025 Results; Core Entertainment Publicity and Marketing Segment (EPM) Revenue Up 2% YoY to $12.1 Million, Strategic Investments and New Division Launch to Drive Long-Term Growth

DLPN

Anghami

BloomZ

Brera Holdings PLC - Class B Ordinary Shares

Brera Holdings

Cineverse

Pop Culture Group Co., Ltd - Class A Ordinary Shares

Pop Culture Gr

Gaia

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Kuke Music Hldg

LiveOne

Moving iMage Technologies, Inc. Common Stock

Moving iMage Technologies

Mega Matrix

NIP Group Inc. - American Depositary Shares

NIP Group

PodcastOne

Reading International Inc - Class A Non-voting Common Stock

Reading Intl

Scienjoy Holding Corporation - Class A Ordinary Shares

Scienjoy Holding

Sound Group Inc. - American Depositary Shares

Sound Group

Brag House Holdings

Kartoon Studios

Maxim Group

Screenshot 2024-05-20 at 5.34.27 PM

Movers & Shakers

Interview

This Leading Entertainment Marketer Reported Over 50% Revenue Growth For Q1 2024

Comments

Dolphin Entertainment

뉴스

에 대한 최신 뉴스 Dolphin Entertainment (NASDAQ:DLPN) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌